Opportunity Information: Apply for PAR 13 013
Apply for PAR 13 013
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Oct 30, 2012 and posted on Oct 30, 2012.
- Applicants must submit their applications by Apr 2, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Special district governments County governments Public housing authorities/Indian housing authorities State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-13-013, titled "Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3)," supports ancillary research projects that make use of archived biospecimens collected during major, well-characterized type 1 diabetes studies: DCCT/EDIC, DPT-1, TrialNet, and GoKind. The central idea is to leverage these existing samples and the rich clinical data that accompany them to answer new scientific questions without having to start new, long-term cohorts from scratch. Projects proposed under this announcement are expected to lead to meaningful discoveries about the primary causes and biological mechanisms of type 1 diabetes, the mechanisms that drive diabetes-related complications, and the identification or validation of biomarkers that track disease progression or predict/reflect clinical responses to interventions.
The opportunity is specifically aimed at studies that can extract additional value from stored specimens, such as blood, serum, plasma, DNA, or other archived materials (depending on what each parent study banked), by applying modern analytic approaches or newly developed assays. Competitive applications would typically be hypothesis-driven and focused on questions that the original trials were not designed or powered to address, for example deeper immune profiling, genetic or genomic analyses, proteomic or metabolomic biomarker discovery, mechanistic studies tied to complication development, or markers that predict who progresses from autoimmunity to clinical disease and who responds to preventive or therapeutic interventions. Because these samples come from landmark clinical trials and networks with standardized procedures and long-term follow-up, the resulting findings can be more clinically interpretable and more generalizable than findings from smaller, less well-characterized collections.
Administratively, this is a discretionary grant program using the NIH DP3 mechanism and falls under the NIH area for Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847). The total estimated funding is listed as $5,000,000 for the program, and there is no cost sharing or matching requirement. The posting and creation date are October 30, 2012, with an original and current closing date of April 2, 2013, and an archive date of May 3, 2013, indicating this particular announcement is no longer open but remains useful as a reference for the goals and expectations of this funding initiative.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants include public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including small businesses and other for-profits); state, county, city/township, and special district governments; independent school districts; public housing authorities/Indian housing authorities; tribal governments and tribal organizations; and a range of mission-focused institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities. Foreign organizations and foreign institutions are also eligible to apply, and foreign components of U.S. organizations are allowed as defined by NIH policy, which signals NIH interest in enabling the best science regardless of geography as long as the project aligns with the program’s goals and policies.
In practical terms, an applicant would be expected to design a study that is feasible with the available archived specimens, justifies the use of these specific cohorts, and demonstrates that the proposed analyses can generate clinically or biologically important insight into type 1 diabetes pathogenesis, complication pathways, or biomarker development. Strong proposals would typically show a clear plan for specimen use, appropriate statistical and analytic methods for working with existing trial datasets, and a credible path from the measured signals to interpretable conclusions about disease biology or clinical outcomes. The full announcement and details were hosted on the NIH Grants Guide at the provided link (http://grants.nih.gov/grants/guide/pa-files/PAR-13-013.html), with the NIH Office of Extramural Research webmaster listed as the contact for access or linking issues.
Frequently Asked Questions (FAQs) - NIH PAR-13-013 (DP3)
What is PAR-13-013?
PAR-13-013 is an NIH funding opportunity titled "Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3)." It supports ancillary research projects that use archived biospecimens and associated clinical data from major, well-characterized type 1 diabetes studies.
What is the main purpose of this funding opportunity?
The purpose is to leverage existing, archived biosamples and rich clinical datasets to answer new scientific questions in type 1 diabetes without starting new long-term cohorts. Projects are expected to produce meaningful discoveries about type 1 diabetes causes and mechanisms, mechanisms of complications, and biomarkers of disease progression or response to interventions.
What grant mechanism does this program use?
This opportunity uses the NIH DP3 grant mechanism.
Which parent clinical studies provide the biosamples for research under this announcement?
The announcement focuses on archived specimens collected in the following type 1 diabetes studies: DCCT/EDIC, DPT-1, TrialNet, and GoKind.
What types of biospecimens can be used?
Projects may use archived biospecimens such as blood, serum, plasma, DNA, or other stored materials. The exact specimen types depend on what was banked by each parent study.
What kinds of research questions are encouraged?
Applications are expected to be geared toward clinically and biologically important questions such as: the primary causes and biological mechanisms of type 1 diabetes; mechanisms that drive diabetes-related complications; and identification or validation of biomarkers that track disease progression or predict/reflect clinical responses to interventions.
What types of analytical approaches are considered a good fit for these archived samples?
The opportunity is aimed at extracting additional value from stored specimens using modern analytic approaches or newly developed assays. Examples described include deeper immune profiling, genetic or genomic analyses, proteomic or metabolomic biomarker discovery, and mechanistic studies related to complication development.
Are projects expected to be hypothesis-driven?
Yes. Competitive applications would typically be hypothesis-driven and focused on questions the original trials were not designed or powered to address.
Why does NIH emphasize using these specific cohorts and samples?
These samples come from landmark clinical trials and networks with standardized procedures and long-term follow-up. That context can make findings more clinically interpretable and more generalizable than results derived from smaller or less well-characterized sample collections.
What is meant by "ancillary research" in this context?
In this announcement, ancillary research refers to new studies that add scientific value by analyzing already-collected and archived specimens and the accompanying clinical data, rather than collecting a brand-new cohort from scratch.
What characteristics would a strong application typically include?
Based on the description provided, strong proposals would typically: demonstrate feasibility using available archived specimens; justify why these specific cohorts are necessary; provide a clear plan for specimen use; use appropriate statistical and analytic methods suited to existing trial datasets; and show a credible path from measured signals to interpretable conclusions about disease biology or clinical outcomes.
What NIH area and CFDA number are associated with this opportunity?
This program falls under the NIH area for Diabetes, Digestive, and Kidney Diseases Extramural Research and is associated with CFDA 93.847.
How much total funding was estimated for the program?
The total estimated funding listed for the program is $5,000,000.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
When was PAR-13-013 posted, and what were the key dates?
The posting and creation date is October 30, 2012. The original and current closing date is April 2, 2013. The archive date is May 3, 2013.
Is this funding opportunity still open?
No. Because the closing date was April 2, 2013 and the archive date was May 3, 2013, this particular announcement is no longer open, though it remains useful as a reference for the program's goals and expectations.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include many types of U.S. and non-U.S. organizations, including public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations; federal-related and local government entities (such as state, county, city/township, and special district governments); independent school districts; public housing authorities/Indian housing authorities; tribal governments and tribal organizations; and mission-focused institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities.
Are foreign organizations allowed to apply?
Yes. Foreign organizations and foreign institutions are eligible to apply.
Are foreign components of U.S. organizations allowed?
Yes. Foreign components of U.S. organizations are allowed as defined by NIH policy.
What would an applicant need to demonstrate about feasibility and specimen availability?
An applicant would be expected to design a study that is feasible with the available archived specimens, including a clear and justified plan for how specimens will be used in the proposed analyses.
Where was the full funding announcement hosted?
The full announcement was hosted on the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-013.html
Who is listed as the contact for access or linking issues?
The NIH Office of Extramural Research webmaster is listed as the contact for access or linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Baird Creek Property Acquisition
Previous opportunity: Water Conservation Field Services Program Great Plains Region, Dakotas Area Office
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Centers for Interdisciplinary Research in Benign Urology (P20) Apply for RFA DK 12 022 Funding Number: RFA DK 12 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Nociceptive GenitoUrinary Development Molecular Anatomy Projects (nGUDMAP) (U01) Apply for RFA DK 12 024 Funding Number: RFA DK 12 024 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 13 028 Funding Number: PAR 13 028 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Stimulating Hematology Investigation New Endeavors (SHINE) (R01) Apply for PAS 13 031 Funding Number: PAS 13 031 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Urologic Chronic Pelvic Pain Syndrome (UCPPS) Research (R01) Apply for RFA DK 12 025 Funding Number: RFA DK 12 025 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| Erythropoiesis Components and Mechanisms (R01) Apply for PA 13 034 Funding Number: PA 13 034 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3) Apply for RFA DK 12 020 Funding Number: RFA DK 12 020 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) Apply for RFA DK 12 021 Funding Number: RFA DK 12 021 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center DILIN DCC(U01) Apply for RFA DK 13 502 Funding Number: RFA DK 13 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Calcium Oxalate Stone Diseases (R01) Apply for PA 13 043 Funding Number: PA 13 043 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for Clinical Trials in Type 1 Diabetes (UC4) Apply for RFA DK 12 511 Funding Number: RFA DK 12 511 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas SBIR (R43/R44) Apply for RFA DK 13 001 Funding Number: RFA DK 13 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Bioengineering Interdisciplinary Training for Diabetes Research (T32) Apply for PAR 13 047 Funding Number: PAR 13 047 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Improved Biomaterials for Urinary and Dialysis Catheters (STTR) (R41/R42) Apply for PA 13 051 Funding Number: PA 13 051 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Improved Biomaterials for Urinary and Dialysis Catheters (SBIR) (R43/R44) Apply for PA 13 050 Funding Number: PA 13 050 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Technological Improvements to Data Collection in NIDDK Kidney and Urology Clinical Studies (SBIR) (R41/R42) Apply for PA 13 053 Funding Number: PA 13 053 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Technological Improvements to Data Collection in NIDDK Kidney and Urology Clinical Studies (SBIR) (R43/R44) Apply for PA 13 052 Funding Number: PA 13 052 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Resource for Human Organs and Tissues (U42) Apply for RFA OD 13 002 Funding Number: RFA OD 13 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Continuation of the Clinical Centers for the Drug Induced Liver Injury Network DILIN (U01) Apply for RFA DK 13 003 Funding Number: RFA DK 13 003 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| Limited Competition of the MAPP Research Network Data Coordinating Core (U01) Apply for RFA DK 13 501 Funding Number: RFA DK 13 501 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.